2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2383

Analysis of the Use of Anticoagulants and Antiplatelet Agents in Strokes Caused By the Deficiency of Adenosine Deaminase 2
Abstract Number: 2384

Variable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in ADA 2 Deficiency
Abstract Number: 2385

Validation of Diary Score for the Assessment of Disease Activity in Candle (Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature) and SAVI (STING associated vasculopathy with onset in Infancy) Patients
Abstract Number: 2386

Role of Pentraxin 3 in Patients with Juvenile Scleroderma
Abstract Number: 2387

Response to Pamidronate Treatment Assessed By Whole Body Magnetic Resonance Imaging in Pediatric Chronic Non-Bacterial Osteomyelitis
Abstract Number: 2388

Clinical Characterization and Outcomes of Pediatric Chronic Nonbacterial Osteomyelitis
Abstract Number: 2389

Is There a Difference in the Presentation of Diffuse and Limited Subtype in Childhood? Results from the Juvenile Scleroderma Inception Cohort
Abstract Number: 2390

Proposal of Assessment of the Activity of Juvenile Localised Scleroderma. Results of the Consensus Meeting in Hamburg, Germany December 2015
Abstract Number: 2391

Update on the Juvenile Systemic Sclerosis Inception Cohort Project. Characteristics of the First 80 Patients at First Assessment
Abstract Number: 2392

Establishing Quality of Life Content Domains in Pediatric Localized Scleroderma
Abstract Number: 2393

Medication Use in the Juvenile Systemic Sclerosis Inception Cohort. ARE There Differences in the Diffuse and Limited Subset Patients?
Abstract Number: 2394

Patient and Parent Global Assessments of Disease Impact in Pediatric Localized Scleroderma: Correlates of Patient Reported Health-Related Quality of Life and Parent Reported Family Impact Domains
Abstract Number: 2395

The Performance of the Kobayashi and Egami Scores in Detecting IVIG Resistance in Kawasaki Disease in a Single Centre Canadian Cohort Treated with IVIG and Low Dose Aspirin
Abstract Number: 2396

Initiation of Dialysis in Pediatric ANCA-Associated Vasculitis
Abstract Number: 2397

Developing a Role for 18f-Flurodeoxyglucose PET/MRI in Pediatric Takayasu Arteritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].